HAMILTON, ON, Aug. 24, 2022 /PRNewswire/ — AtomVie Global Radiopharma Inc. (“AtomVie”) at this time introduced the profitable closing of its Series A financing with Avego Management, LLC (“Avego”), a healthcare funding agency. AtomVie is a world main CDMO (Contract Development and Manufacturing Organization) for the event, manufacturing, and world distribution of radiopharmaceuticals and has acquired a financing dedication of at the very least $40 million.
AtomVie is a spinout from the CPDC (Centre for Probe Development and Commercialization), and inside CPDC, the CMO business unit, now AtomVie, served because the GMP producer and provider of finished-dose therapeutic radiopharmaceuticals for the previous seven years. AtomVie will likely be increasing its present scientific GMP manufacturing capability of radiopharmaceutical merchandise to incorporate business stage manufacturing by way of the development of a brand new purpose-built state-of-the-art facility designed to accommodate a number of isotopes. Moreover, AtomVie enhances its manufacturing and logistics experience with a high-standard high quality administration system and world regulatory help.
“We worked relentlessly over the past few years in preparation of this moment,” mentioned Bruno Paquin, CEO of AtomVie. “All the employees at AtomVie are extremely grateful to Avego for their support and their confidence. We are excited to launch AtomVie, continuing the culture of excellence that the CPDC has created and working with Avego for the long-term success of AtomVie.”
“Avego is thrilled to partner with AtomVie to support the continued growth of one of the leading radiopharmaceutical CDMOs,” mentioned Thomas Vandervort, Managing Partner of Avego. “The AtomVie team and their collective radiopharmaceutical expertise are second to none, and our partnership will advance the development of radiopharmaceuticals and improve patient outcomes.”
AtomVie has strengthened its operational administration with the latest appointment of Dodi Adar, Chief Operating Officer and the promotion of Rezwan Ashique, VP Operations. Ms. Adar brings 17 years of expertise within the pharmaceutical trade with experience in fostering development and streamlining operational processes. Mr. Ashique was an instrumental a part of CPDC’s success for over eight years with greater than 20 years of intensive experience in radiochemistry, growth, and GMP manufacturing of ready-to-use radiopharmaceuticals.
With its world-class staff and its in-depth expertise within the radiopharmaceutical trade, AtomVie empowers the event of next-generation radiotherapeutics worldwide.
AtomVie, integrated in late 2021, is a world main CDMO for the GMP manufacturing and distribution of scientific and business radiopharmaceuticals and figures as the newest spinout from the CPDC. Founded in 2008, the CPDC is a CECR (Centre of Excellence for Commercialization and Research) situated at McMaster University in Hamilton, Ontario, Canada. The CPDC was created with the long-time help from the NCE (Networks of Centres of Excellence), McMaster University and the OICR (Ontario Institute for Cancer Research). The experience developed on the CPDC and its place as a world main CDMO is the stepping stone for AtomVie spinout. For extra details about AtomVie, go to www.atomvie.com or contact: [email protected]. To be taught extra about CPDC, go to www.imagingprobes.ca or contact: [email protected].
Avego, based in 2015 by former healthcare entrepreneurs, is a multi-strategy healthcare-focused funding agency with workplaces in Georgia and New York. Through its three methods, which embody non-public fairness, enterprise capital, and a hedge fund, Avego invests in non-public and public firms growing and commercializing modern merchandise and companies for sufferers, practitioners, and different stakeholders throughout the healthcare continuum. To be taught extra about Avego, go to www.avego.com or contact: [email protected].
Logo – https://mma.prnewswire.com/media/1882482/AtomVie_Global_Radiopharma_Inc__AtomVie_Global_Radiopharma_Inc_.jpg
Logo – https://mma.prnewswire.com/media/1882483/AtomVie_Global_Radiopharma_Inc__AtomVie_Global_Radiopharma_Inc_.jpg
